These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 31768949

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R, Lai MC, Beswick A, Gorman DA, Anagnostou E, Szatmari P, Anderson KK, Ameis SH.
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [Abstract] [Full Text] [Related]

  • 3. Impact of a restrictive drug access program on the risk of cardiovascular encounters in children exposed to ADHD medications.
    Guertin J, LeLorier J, Durand M, Gow R, Holbrook A, Levine M.
    J Popul Ther Clin Pharmacol; 2014 Jun; 21(3):e357-69. PubMed ID: 25326915
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S, Nielsen HS, Simonsen M.
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [Abstract] [Full Text] [Related]

  • 7. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P.
    CNS Drugs; 2015 Sep; 29(10):865-77. PubMed ID: 26293742
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Psychiatric Comorbidities and Psychotropic Medication Use in Autism: A Matched Cohort Study with ADHD and General Population Comparator Groups in the United Kingdom.
    Houghton R, Liu C, Bolognani F.
    Autism Res; 2018 Dec; 11(12):1690-1700. PubMed ID: 30380202
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
    Patra S, Nebhinani N, Viswanathan A, Kirubakaran R.
    Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of dystonia in children and adolescents treated with atomoxetine within the Truven MarketScan database: a retrospective cohort study.
    Meyers KJ, Upadhyaya HP, Goodloe R, Kryzhanovskaya LA, Liles-Burden MA, Kellier-Steele NA, Mancini M.
    Expert Opin Drug Saf; 2018 May; 17(5):467-473. PubMed ID: 29625537
    [Abstract] [Full Text] [Related]

  • 19. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
    Arnold LE, Ober N, Aman MG, Handen B, Smith T, Pan X, Hyman SL, Hollway J, Lecavalier L, Page K, Rice R.
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.